Iovance Biotherapeutics, Inc. (IOVA)
Automate Your Wheel Strategy on IOVA
With Tiblio's Option Bot, you can configure your own wheel strategy including IOVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IOVA
- Rev/Share 0.6587
- Book/Share 2.3783
- PB 0.7695
- Debt/Equity 0.07
- CurrentRatio 4.1783
- ROIC -0.4632
- MktCap 611099220.0
- FreeCF/Share -1.0763
- PFCF -1.7586
- PE -1.5741
- Debt/Assets 0.0556
- DivYield 0
- ROE -0.4971
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IOVA | UBS | Buy | Neutral | -- | $2 | May 16, 2025 |
| Downgrade | IOVA | Truist | Buy | Hold | -- | -- | May 12, 2025 |
| Downgrade | IOVA | Citizens JMP | Mkt Outperform | Market Perform | -- | -- | May 9, 2025 |
News
Investor Alert: Deadline Approaching to Join Iovance Biotherapeutics, Inc. (IOVA) Class Action - Contact Levi & Korsinsky
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149693&wire=1&utm_campaign=25 or contact Joseph E. Levi, Esq.
Read More
IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW ORLEANS, May 21, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Read More
IOVA ALERT: Iovance Biotherapeutics, Inc. was Sued for Securities Fraud after 44% Stock Drop -- Contact BFA Law if You Suffered Losses
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Published: May 21, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm.
Read More
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit – IOVA
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
Read More
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Contact Levi & Korsinsky Before July 14, 2025 to Join Class Action
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149626&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.
Read More
ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than July 14, 2025.
Read More
Class Action Alert: Levi & Korsinsky Reminds Iovance (IOVA) Investors of July 14, 2025 Deadline
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149617&wire=1&utm_campaign=17 or contact Joseph E. Levi, Esq.
Read More
Scott+Scott Attorneys at Law LLP Alerts Investors an Action Has Been Filed Against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, alerts investors that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. …
Read More
Iovance Biotherapeutics (IOVA) Faces Investor Lawsuit Over Growth Projections Following Stock Plunge - Hagens Berman
Published: May 21, 2025 by: PRNewsWire
Sentiment: Neutral
IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , May 21, 2025 /PRNewswire/ -- Biotechnology firm Iovance Biotherapeutics, Inc. (NASSAQ: IOVA) is facing a securities class action lawsuit in the Northern District of California, alleging that the company misled investors about its growth potential and ability to capitalize on demand for its cancer treatments. The case, Farberov v.
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149515&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.
Read More
IOVA LAWSUIT: Lose Money on Iovance Biotherapeutics, Inc.? Contact BFA Law before July 14 Court Deadline
Published: May 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Class Action Lawsuit Filed: Iovance Biotherapeutics, Inc. (IOVA) - Join by July 14, 2025 - Contact Levi & Korsinsky
Published: May 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149508&wire=1&utm_campaign=8 or contact Joseph E. Levi, Esq.
Read More
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149473&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Continues Lead Plaintiff Search for Iovance Biotherapeutics, Inc. (IOVA) Securities Fraud Class Action
Published: May 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, May 20, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with losses in excess of $100,000 that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Read More
Down More Than 75% This Year, Should Investors Throw in the Towel on Iovance Biotherapeutics Stock?
Published: May 20, 2025 by: The Motley Fool
Sentiment: Neutral
Entering trading this week, shares of Iovance Biotherapeutics (IOVA 4.10%) have crashed by nearly 78% since the start of the year. It has been an abysmal start to 2025 for a company that does possess some attractive long-term growth prospects.
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Investors - Lead Plaintiff Deadline on July 14, 2025
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149453&wire=1&utm_campaign=14 or contact Joseph E. Levi, Esq.
Read More
Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. (IOVA) Shareholders of Class Action Lawsuit and July 14, 2025 Deadline
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149450&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.
Read More
ROSEN, A TOP - RANKED INVESTOR RIGHTS FIRM, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IOVA
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / WHY: New York, N.Y., May 20, 2025.
Read More
Deadline Approaching: Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
Published: May 20, 2025 by: Business Wire
Sentiment: Neutral
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming July 14, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIP.
Read More
Securities Lawsuit Alert: Iovance Biotherapeutics, Inc. (IOVA) - Contact Levi & Korsinsky Before July 14, 2025
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149414&wire=1&utm_campaign=3 or contact Joseph E. Levi, Esq.
Read More
IOVA NOTIFICATION: A Class Action Has Been Filed on Behalf of Iovance Biotherapeutics, Inc. Investors - Contact BFA Law by July 14 Legal Deadline
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/iovance-biotherapeutics-inc-class-action-lawsuit.
Read More
Contact Levi & Korsinsky by July 14, 2025 to Join Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
Published: May 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149407&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
Read More
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) Seeking Recovery for Investors - Contact The Gross Law Firm
Published: May 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , May 19, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA). Shareholders who purchased shares of IOVA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Read More
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
Read More
Levi & Korsinsky Urges Iovance (IOVA) Shareholders to Act Before Lead Plaintiff Deadline July 14, 2025
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149244&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.
Read More
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors - Lead Plaintiff Deadline July 14, 2025
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149239&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Iovance Biotherapeutics, Inc. - IOVA
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ:IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
LOS ANGELES--(BUSINESS WIRE)--Law Offices of Frank R. Cruz Encourages Iovance Biotherapeutics, Inc. (IOVA) Investors To Inquire About Securities Fraud Class Action.
Read More
Investors in Iovance Biotherapeutics, Inc. (IOVA): Protect Your Rights - Contact Levi & Korsinsky Before July 14, 2025
Published: May 19, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=149222&wire=1&utm_campaign=11 or contact Joseph E. Levi, Esq.
Read More
About Iovance Biotherapeutics, Inc. (IOVA)
- IPO Date 2010-10-15
- Website https://www.iovance.com
- Industry Biotechnology
- CEO Dr. Frederick G. Vogt Esq., J.D., Ph.D.
- Employees 838